Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Fuji
Deloitte
Medtronic
Cantor Fitzgerald
QuintilesIMS
Moodys
Covington
Baxter

Generated: December 13, 2018

DrugPatentWatch Database Preview

XOFIGO Drug Profile

« Back to Dashboard

When do Xofigo patents expire, and what generic alternatives are available?

Xofigo is a drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-four patent family members in twenty-one countries.

The generic ingredient in XOFIGO is radium ra-223 dichloride. One supplier is listed for this compound. Additional details are available on the radium ra-223 dichloride profile page.

Summary for XOFIGO
International Patents:34
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 19
Drug Prices: Drug price information for XOFIGO
DailyMed Link:XOFIGO at DailyMed
Drug patent expirations by year for XOFIGO

US Patents and Regulatory Information for XOFIGO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare XOFIGO radium ra-223 dichloride SOLUTION;INTRAVENOUS 203971-001 May 15, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Hlthcare XOFIGO radium ra-223 dichloride SOLUTION;INTRAVENOUS 203971-001 May 15, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for XOFIGO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1140212/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: RADIUM RA-223; REGISTRATION NO/DATE: SWISSMEDIC 62732 29.08.2014
C0038 France ➤ Try a Free Trial PRODUCT NAME: RADIUM 223 AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES,EN PARTICULIER LE DICHLORURE DE RADIUM 223; REGISTRATION NO/DATE: EU/1/13/873 20131113
2014 00027 Denmark ➤ Try a Free Trial PRODUCT NAME: RADIUM-223 OG OPLOESELIGE SALTE DERAF, HERUNDER RADIUM-223 DICHLORID; REG. NO/DATE: EU/1/13/873 20131113
2014 00027 Denmark ➤ Try a Free Trial PRODUCT NAME: RADIUM-223 OG OPLOESELIGE SALTE DERAF, HERUNDER RADIUM-223 DICHLORID; REG. NO/DATE: EU/1/13/873 20131113
2014000052 Germany ➤ Try a Free Trial PRODUCT NAME: RADIUM-223-SALZ, INSBESONDERE RADIUM-223-DICHLORID; REGISTRATION NO/DATE: EU/1/13/873 20131113
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
McKinsey
Boehringer Ingelheim
Argus Health
US Army
Baxter
Merck
QuintilesIMS
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.